31.10

2.29% -0.7116

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is traded at $31.10, with a volume of 90,796. It is down -2.29% in the last 24 hours and down -16.38% over the past month. Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Previous Close:

$31.81

Open:

$31.73

24h Volume:

90,796

Relative Volume:

0.09

Market Cap:

$1.85B

Revenue:

$13.05M

Net Income/Loss:

$-60.54M

P/E Ratio:

-26.81

EPS:

-1.16

Net Cash Flow:

$-37.82M

1W Performance:

+1.07%

1M Performance:

-16.38%

6M Performance:

-37.85%

1Y Performance:

-22.14%

1-Day Range:

$31.00

$32.29

1-Week Range:

$28.92

$32.29

52-Week Range:

$28.92

$71.71

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

(858) 751-4493

Address

10955 VISTA SORRENTO PARKWAY, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-08-06

Latest SEC Filings

JANX's Discussions on Twitter

Compare JANX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
JANX Janux Therapeutics Inc	31.04	1.85B	13.05M	-60.54M	-37.82M	-1.16
VRTX Vertex Pharmaceuticals Inc	503.02	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	686.39	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.20	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.49	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.10	26.76B	3.32B	-860.46M	-1.04B	-8.32

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-03-24	Reiterated	BTIG Research	Buy
Dec-03-24	Reiterated	H.C. Wainwright	Buy
Nov-22-24	Initiated	Leerink Partners	Outperform
Oct-24-24	Initiated	UBS	Buy
Sep-06-24	Initiated	Stifel	Buy
May-30-24	Initiated	Scotiabank	Sector Perform
Mar-21-24	Initiated	BTIG Research	Buy
Mar-20-24	Initiated	Cantor Fitzgerald	Overweight
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

View All

Janux Therapeutics Inc Stock (JANX) Latest News

Mar 12, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Mar 12, 2025

EGFR Non-Small Cell Lung Cancer Clinical and Non-Clinical - openPR

Mar 12, 2025

Janux Therapeutics (NASDAQ:JANX) Shares Gap Up Following Insider Buying Activity - Defense World

Mar 12, 2025

Mar 11, 2025

Insiders Are Loading Up on These 4 Biotech Stocks Now - 24/7 Wall St.

Mar 11, 2025

(JANX) Proactive Strategies - Stock Traders Daily

Mar 11, 2025

Mar 10, 2025

JANX stock touches 52-week low at $29.62 amid market shifts By Investing.com - Investing.com South Africa

Mar 10, 2025

JANX stock touches 52-week low at $29.62 amid market shifts - Investing.com India

Mar 10, 2025

Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures - Investing.com India

Mar 10, 2025

Sunday Insider Moves: Top Buys and Sells from Friday’s Disclosures By Investing.com - Investing.com Canada

Mar 10, 2025

Mar 09, 2025

Ra Capital Management, L.P. Purchases 341,742 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World

Mar 09, 2025

Ra Capital Management, L.P. Purchases 110,206 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock - Defense World

Mar 09, 2025

Mar 08, 2025

Major Investment Alert: Janux Therapeutics Stock Sees Massive Buy-In! - TipRanks

Mar 08, 2025

Proficio Capital Partners LLC Invests $1.35 Million in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World

Mar 08, 2025

Mar 07, 2025

Ra capital management buys $25.3 million in Janux therapeutics stock By Investing.com - Investing.com South Africa

Mar 07, 2025

Ra capital management buys $25.3 million in Janux therapeutics stock - Investing.com

Mar 07, 2025

HC Wainwright Has Pessimistic Outlook of JANX Q1 Earnings - Defense World

Mar 07, 2025

Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Friday - Defense World

Mar 07, 2025

Mar 06, 2025

Janux Therapeutics chief business officer sells shares for $107,174 By Investing.com - Investing.com South Africa

Mar 06, 2025

Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages - Defense World

Mar 06, 2025

Mar 05, 2025

Janux Therapeutics chief business officer sells shares for $107,174 - Investing.com India

Mar 05, 2025